AnalyzeDirect

binger M, Christensen S, De Silva DA, Parsons MW, Levi CR, Butcher KS, Bladin CF, Barber PA, Donnan GA, Davis SM. Expediting MRI-based proof-of-concept stroke trials using an earlier imaging end point. Stroke. April 2009;40(4):1353-1358.

Full Text – Open Access

Publication Date
April 2009

How Analyze was Used
“All MRI scans were read at the coordinating center by investigators blinded to treatment assignment and clinical outcomes but not to time point. DWI at baseline and Days 3 to 5 and T2-weighted lesions at Day 90 were assessed by 2 independent raters who used standard planimetric software (Analyze 7.0).”

Keywords
Acute Disease
Aged
Aged, 80 and over
Brain Ischemia/drug therapy/pathology
Echo-Planar Imaging
Female
Fibrinolytic Agents/therapeutic use
Humans
Male
Middle Aged
Placebos
Stroke/drug therapy/pathology
Time Factors
Tissue Plasminogen Activator/therapeutic use
Treatment Outcome

Author Affiliation(s)
Department of Neurology, The Royal Melbourne Hospital, Parkville, Australia. (ME, SC, DADS, SMD)

Department of Neurology and Hunter Medical Research Institute, John Hunter Hospital, University of Newcastle, Australia. (MWP, CRL)

Faculty of Medicine and Dentistry, University of Alberta, Edmonton, Canada. (KSB)

Department of Neurology, Box Hill Hospital, Monash University, Melbourne, Australia. (CFB)

Department of Neurology, Auckland Hospital, Auckland, New Zealand. (PAB)

Department of Neurology, Austin Hospital, Melbourne, Australia. (GAD)

ID# 1215

Tags: Acute Disease, Aged, Aged_80 and over, Brain Ischemia/drug therapy/pathology, Echo-Planar Imaging, Female, Fibrinolytic Agents/therapeutic use, Humans, Male, Middle Aged, Placebos, Stroke/drug therapy/pathology, Time Factors, Tissue Plasminogen Activator/therapeutic use, Treatment Outcome